Found this on raging bull:
More info on what could possibly put AZT, 3TC and all the other antiviral drugs into obsolescence! Viral Genetics has developed a treatment for HIV and AIDS patients that has proven to be extremely effective in clinical trials. All disclosure documents have been filed with the SEC to complete the merger with 5 Starliving Online Inc., (OTC BB:HTHV).
Click on this link to view the press release: biz.yahoo.com
1.Viral Genetics, of Pasadena California, has developed a treatment for HIV and AIDS patients that has thus far proven to be extremely effective in clinical trials. That treatment, known as TNP, could possibly put AZT, 3TC and all the other antiviral drugs into obsolescence.
2.The three trials to date have been conducted with protocols modeled after FDA standards, and all blood samples were independently tested at Specialty Labs in Santa Monica, California.
3.Testing of patients that received the TNP treatment showed marked decreases in Viral load and increases in cell mediated immune response. Many patients actually started to regain lost body weight during and after treatment. Patients that had become "non responders" to AZT/PI cocktails experienced measurable improvements after undergoing treatment with TNP.
4.VG’s treatment is a one time only therapy, received over an eight week period, as opposed to the current treatments which require patients to ingest up to ten or more pills on a daily basis for the rest of their lives.
5.VG clinical patients suffered negligible side effects from TNP, such as fatigue, whereas other HIV treatments are known for their debilitating side effects.
6.VG has projected that the one-time cost of the TNP treatment will be substantially less than the $10,000 to $12,000 that an HIV patient pays on a recurring annual basis for the currently preferred treatment.
7.VG has commenced the process of gaining US FDA approval. The Company has already filed an Investigational New Drug Application (IND) with the FDA and expects to be fast-tracked.
8.VG will proceed with FDA clinical trials once the IND is accepted; The initial funding is already in place to conduct the research.
9.Worldwide PCT patent applications have been filed in many key countries including the U.S., the European Union, Canada, China, Brazil and several others. The company has been issued patents in New Zealand, South Africa, Australia, Eurasia, and Israel.
10.VG is very close to gaining commercial approval for the treatment in Mexico and Malaysia. The Company expects their first private sales to come in Mexico by the Spring of 2002. Gaining commercial approval in Mexico will effectively open the door to the huge market of Central and South America.
11.The company feels that successful results in the US, even at the six-month milestone, will create numerous opportunities including a joint venture licensing agreement(s) with major US and international pharmaceutical companies and rapid acceptance and approval for sales in international markets.
12.VG has forecasted revenues of $325 mil and $528 mil for fiscal years '02 and '03; Net earnings on those sales are projected at $28 mil and $100 mil respectively. |
